展望Therapeutics Q3 2024调整后每股收益$（0.83）优于$（1.01）预期

Outlook Therapeutics (NASDAQ: OTLK) reported quarterly losses of $(0.83) per share which beat the analyst consensus estimate of $(1.01) by 17.82 percent. This is a 39.86 percent increase over losses of $(1.38) per share from the same period last year.